All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Participant-reported quality of the denture (general satisfaction) · Completely edentulous people
It is very uncertain whether single-stage alginate impression (simplified method) changes participant-reported quality of the denture (general satisfaction) compared with two stage-two step zinc-oxide eugenol (ZoE) traditional method (very low certainty).
1 finding from 1 review
Number of border adjustments and sore spots after insertion of denture · Completely edentulous people
The review found no eligible studies for this question.
1 finding from 1 review
Not measured
0 studies
No studies found
Operator-assessed quality of the denture · Completely edentulous people
1 finding from 1 review
Participant-reported quality of the denture (general satisfaction) · Completely edentulous people
It is very uncertain whether single-stage alginate impression (simplified method) changes participant-reported quality of the denture (general satisfaction,… compared with two stage-two step elastomer (silicone, polysulfide, or polyether)… (very low certainty).
1 finding from 1 review
Oral health-related quality of life · Completely edentulous people
It is very uncertain whether single-stage alginate impression (simplified method) changes participant-reported oral health-related quality of life (OHIP-EDENT) compared with two stage-two step zinc-oxide eugenol (ZoE) traditional method (very low certainty).
1 finding from 1 review
Mandibular denture satisfaction · Completely edentulous people
It is very uncertain whether single-stage alginate impression (simplified method) changes mandibular denture satisfaction compared with two stage-two step elastomer (silicone, polysulfide, or polyether)… (very low certainty).
1 finding from 1 review
Maxillary denture satisfaction · Completely edentulous people
It is very uncertain whether single-stage alginate impression (simplified method) changes maxillary denture satisfaction compared with two stage-two step elastomer (silicone, polysulfide, or polyether)… (very low certainty).
1 finding from 1 review
Oral health-related quality of life · Completely edentulous people
It is very uncertain whether single-stage alginate impression (simplified method) changes participant-reported oral health-related quality of life (OHIP-EDENT) compared with two stage-two step elastomer (silicone, polysulfide, or polyether)… (very low certainty).
1 finding from 1 review
Operator-assessed quality of the denture (retention and stability) · Completely edentulous people
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review